CorMedix Q1 net revenue $127.4M, net income $38.6M; raises FY guidance

CorMedix Inc.

Q1 net revenue $127.4M, net income $38.6M, adjusted EBITDA $70.0M; EPS $0.48 basic/$0.43 diluted.
DefenCath revenue $97.5M (incl. $9.0M favorable estimate change); Melinta portfolio $29.9M.
Raises FY2026 guidance: net revenue $325-345M, adjusted EBITDA $115-135M.
Positive Phase III topline for REZZAYO prophylaxis; sNDA submission H2 2026, potential launch 2027.
Cash and investments $178.1M; TPN study trending to 2028, actions to accelerate enrollment.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CorMedix Inc. reported the first quarter ended March 31, 2026 results: revenue $127.4 million, net income $38.6 million, EPS $0.48 and $0.43 per share. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $127.4 million
Net income: $38.6 million
EPS: $0.48 and $0.43 per share
Guidance: raised
Result: reported results

Exact text from the filing

reference in such a filing. --- EX-99.1 (EX-99.1) --- CORMEDIX THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today

View on SEC.gov

Browse all earnings releases →

CorMedix Inc. filing history →

Source: SEC EDGAR

accession 0001410098-26-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.